Nymox Pharmaceutical Corporation (NYMXF)
OQB · Healthcare · Biotechnology
$0.10
+1.36%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$9.2M
Shares Outstanding
94.5M
Exchange
OQB
Currency
USD
About Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.